カテゴリー： Market Monitor Global, 世界, 医療/バイオ

乳がん免疫療法のグローバル市場展望 2023年-2029年：モノクローナル抗体、免疫チェックポイント阻害剤、がんワクチン、その他

◆英語タイトル：Breast Cancer Immunotherapy Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23DC12274）

◆商品コード：MMG23DC12274
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年12月
◆ページ数：68
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の乳がん免疫療法市場規模と予測を収録しています。・世界の乳がん免疫療法市場：売上、2018年-2023年、2024年-2029年
・世界の乳がん免疫療法市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の乳がん免疫療法市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「モノクローナル抗体」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

乳がん免疫療法のグローバル主要企業は、Roche、 Genentech、 Amgen、 Antibody Therapeutics、 Pfizer、 Merck、 Novartis、 Bristol Myers Squibb、 Squibb、 EirGenix、 Prestige BioPharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、乳がん免疫療法のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の乳がん免疫療法市場：タイプ別、2018年-2023年、2024年-2029年
世界の乳がん免疫療法市場：タイプ別市場シェア、2022年
・モノクローナル抗体、免疫チェックポイント阻害剤、がんワクチン、その他

世界の乳がん免疫療法市場：用途別、2018年-2023年、2024年-2029年
世界の乳がん免疫療法市場：用途別市場シェア、2022年
・病院、がん研究センター、小売薬局

世界の乳がん免疫療法市場：地域・国別、2018年-2023年、2024年-2029年
世界の乳がん免疫療法市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における乳がん免疫療法のグローバル売上、2018年-2023年
・主要企業における乳がん免疫療法のグローバル売上シェア、2022年
・主要企業における乳がん免疫療法のグローバル販売量、2018年-2023年
・主要企業における乳がん免疫療法のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Roche、 Genentech、 Amgen、 Antibody Therapeutics、 Pfizer、 Merck、 Novartis、 Bristol Myers Squibb、 Squibb、 EirGenix、 Prestige BioPharma

*************************************************************

・調査・分析レポートの概要
乳がん免疫療法市場の定義
市場セグメント
世界の乳がん免疫療法市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の乳がん免疫療法市場規模
世界の乳がん免疫療法市場規模：2022年 VS 2029年
世界の乳がん免疫療法市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの乳がん免疫療法の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の乳がん免疫療法製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：モノクローナル抗体、免疫チェックポイント阻害剤、がんワクチン、その他
乳がん免疫療法のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、がん研究センター、小売薬局
乳がん免疫療法の用途別グローバル売上・予測

・地域別市場分析
地域別乳がん免疫療法市場規模 2022年と2029年
地域別乳がん免疫療法売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Roche、 Genentech、 Amgen、 Antibody Therapeutics、 Pfizer、 Merck、 Novartis、 Bristol Myers Squibb、 Squibb、 EirGenix、 Prestige BioPharma
...

This research report provides a comprehensive analysis of the Breast Cancer Immunotherapy market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Breast Cancer Immunotherapy market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Breast Cancer Immunotherapy, challenges faced by the industry, and potential opportunities for market players.
The global Breast Cancer Immunotherapy market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Breast Cancer Immunotherapy market presents opportunities for various stakeholders, including Hospitals, Cancer Research Centres. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Breast Cancer Immunotherapy market. Additionally, the growing consumer demand present avenues for market expansion.
The global Breast Cancer Immunotherapy market was valued at US$ 21330 million in 2022 and is projected to reach US$ 59110 million by 2029, at a CAGR of 15.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Breast Cancer Immunotherapy market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Breast Cancer Immunotherapy market.
Market Overview: The report provides a comprehensive overview of the Breast Cancer Immunotherapy market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Monoclonal Antibodies, Immune Checkpoint Inhibitors）, region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Breast Cancer Immunotherapy market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Breast Cancer Immunotherapy market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Breast Cancer Immunotherapy market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Breast Cancer Immunotherapy market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Breast Cancer Immunotherapy market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Breast Cancer Immunotherapy market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Breast Cancer Immunotherapy, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Breast Cancer Immunotherapy market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Breast Cancer Immunotherapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Cancer Vaccines
Others
Market segment by Application
Hospitals
Cancer Research Centres
Retail Pharmacies
Global Breast Cancer Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%）
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Roche
Genentech
Amgen
Antibody Therapeutics
Pfizer
Merck
Novartis
Bristol Myers Squibb
Squibb
EirGenix
Prestige BioPharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Breast Cancer Immunotherapy, market overview.
Chapter 2: Global Breast Cancer Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Breast Cancer Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Breast Cancer Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Breast Cancer Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Breast Cancer Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Breast Cancer Immunotherapy Overall Market Size
2.1 Global Breast Cancer Immunotherapy Market Size: 2022 VS 2029
2.2 Global Breast Cancer Immunotherapy Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Breast Cancer Immunotherapy Players in Global Market
3.2 Top Global Breast Cancer Immunotherapy Companies Ranked by Revenue
3.3 Global Breast Cancer Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 Breast Cancer Immunotherapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Breast Cancer Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Breast Cancer Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 Breast Cancer Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Breast Cancer Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Breast Cancer Immunotherapy Market Size Markets, 2022 & 2029
4.1.2 Monoclonal Antibodies
4.1.3 Immune Checkpoint Inhibitors
4.1.4 Cancer Vaccines
4.1.5 Others
4.2 By Type – Global Breast Cancer Immunotherapy Revenue & Forecasts
4.2.1 By Type – Global Breast Cancer Immunotherapy Revenue, 2018-2023
4.2.2 By Type – Global Breast Cancer Immunotherapy Revenue, 2024-2029
4.2.3 By Type – Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Breast Cancer Immunotherapy Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Cancer Research Centres
5.1.4 Retail Pharmacies
5.2 By Application – Global Breast Cancer Immunotherapy Revenue & Forecasts
5.2.1 By Application – Global Breast Cancer Immunotherapy Revenue, 2018-2023
5.2.2 By Application – Global Breast Cancer Immunotherapy Revenue, 2024-2029
5.2.3 By Application – Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Breast Cancer Immunotherapy Market Size, 2022 & 2029
6.2 By Region – Global Breast Cancer Immunotherapy Revenue & Forecasts
6.2.1 By Region – Global Breast Cancer Immunotherapy Revenue, 2018-2023
6.2.2 By Region – Global Breast Cancer Immunotherapy Revenue, 2024-2029
6.2.3 By Region – Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Breast Cancer Immunotherapy Revenue, 2018-2029
6.3.2 US Breast Cancer Immunotherapy Market Size, 2018-2029
6.3.3 Canada Breast Cancer Immunotherapy Market Size, 2018-2029
6.3.4 Mexico Breast Cancer Immunotherapy Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Breast Cancer Immunotherapy Revenue, 2018-2029
6.4.2 Germany Breast Cancer Immunotherapy Market Size, 2018-2029
6.4.3 France Breast Cancer Immunotherapy Market Size, 2018-2029
6.4.4 U.K. Breast Cancer Immunotherapy Market Size, 2018-2029
6.4.5 Italy Breast Cancer Immunotherapy Market Size, 2018-2029
6.4.6 Russia Breast Cancer Immunotherapy Market Size, 2018-2029
6.4.7 Nordic Countries Breast Cancer Immunotherapy Market Size, 2018-2029
6.4.8 Benelux Breast Cancer Immunotherapy Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Breast Cancer Immunotherapy Revenue, 2018-2029
6.5.2 China Breast Cancer Immunotherapy Market Size, 2018-2029
6.5.3 Japan Breast Cancer Immunotherapy Market Size, 2018-2029
6.5.4 South Korea Breast Cancer Immunotherapy Market Size, 2018-2029
6.5.5 Southeast Asia Breast Cancer Immunotherapy Market Size, 2018-2029
6.5.6 India Breast Cancer Immunotherapy Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Breast Cancer Immunotherapy Revenue, 2018-2029
6.6.2 Brazil Breast Cancer Immunotherapy Market Size, 2018-2029
6.6.3 Argentina Breast Cancer Immunotherapy Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Breast Cancer Immunotherapy Revenue, 2018-2029
6.7.2 Turkey Breast Cancer Immunotherapy Market Size, 2018-2029
6.7.3 Israel Breast Cancer Immunotherapy Market Size, 2018-2029
6.7.4 Saudi Arabia Breast Cancer Immunotherapy Market Size, 2018-2029
6.7.5 UAE Breast Cancer Immunotherapy Market Size, 2018-2029
7 Breast Cancer Immunotherapy Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Breast Cancer Immunotherapy Major Product Offerings
7.1.4 Roche Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.1.5 Roche Key News & Latest Developments
7.2 Genentech
7.2.1 Genentech Company Summary
7.2.2 Genentech Business Overview
7.2.3 Genentech Breast Cancer Immunotherapy Major Product Offerings
7.2.4 Genentech Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.2.5 Genentech Key News & Latest Developments
7.3 Amgen
7.3.1 Amgen Company Summary
7.3.2 Amgen Business Overview
7.3.3 Amgen Breast Cancer Immunotherapy Major Product Offerings
7.3.4 Amgen Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.3.5 Amgen Key News & Latest Developments
7.4 Antibody Therapeutics
7.4.1 Antibody Therapeutics Company Summary
7.4.2 Antibody Therapeutics Business Overview
7.4.3 Antibody Therapeutics Breast Cancer Immunotherapy Major Product Offerings
7.4.4 Antibody Therapeutics Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.4.5 Antibody Therapeutics Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Breast Cancer Immunotherapy Major Product Offerings
7.5.4 Pfizer Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.5.5 Pfizer Key News & Latest Developments
7.6 Merck
7.6.1 Merck Company Summary
7.6.2 Merck Business Overview
7.6.3 Merck Breast Cancer Immunotherapy Major Product Offerings
7.6.4 Merck Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.6.5 Merck Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Breast Cancer Immunotherapy Major Product Offerings
7.7.4 Novartis Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.7.5 Novartis Key News & Latest Developments
7.8 Bristol Myers Squibb
7.8.1 Bristol Myers Squibb Company Summary
7.8.2 Bristol Myers Squibb Business Overview
7.8.3 Bristol Myers Squibb Breast Cancer Immunotherapy Major Product Offerings
7.8.4 Bristol Myers Squibb Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.8.5 Bristol Myers Squibb Key News & Latest Developments
7.9 Squibb
7.9.1 Squibb Company Summary
7.9.2 Squibb Business Overview
7.9.3 Squibb Breast Cancer Immunotherapy Major Product Offerings
7.9.4 Squibb Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.9.5 Squibb Key News & Latest Developments
7.10 EirGenix
7.10.1 EirGenix Company Summary
7.10.2 EirGenix Business Overview
7.10.3 EirGenix Breast Cancer Immunotherapy Major Product Offerings
7.10.4 EirGenix Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.10.5 EirGenix Key News & Latest Developments
7.11 Prestige BioPharma
7.11.1 Prestige BioPharma Company Summary
7.11.2 Prestige BioPharma Business Overview
7.11.3 Prestige BioPharma Breast Cancer Immunotherapy Major Product Offerings
7.11.4 Prestige BioPharma Breast Cancer Immunotherapy Revenue in Global Market (2018-2023）
7.11.5 Prestige BioPharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Breast Cancer Immunotherapy Market Opportunities & Trends in Global Market
Table 2. Breast Cancer Immunotherapy Market Drivers in Global Market
Table 3. Breast Cancer Immunotherapy Market Restraints in Global Market
Table 4. Key Players of Breast Cancer Immunotherapy in Global Market
Table 5. Top Breast Cancer Immunotherapy Players in Global Market, Ranking by Revenue (2022）
Table 6. Global Breast Cancer Immunotherapy Revenue by Companies, (US$, Mn）, 2018-2023
Table 7. Global Breast Cancer Immunotherapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Breast Cancer Immunotherapy Product Type
Table 9. List of Global Tier 1 Breast Cancer Immunotherapy Companies, Revenue (US$, Mn） in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Breast Cancer Immunotherapy Companies, Revenue (US$, Mn） in 2022 and Market Share
Table 11. By Type – Global Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2022 & 2029
Table 12. By Type - Breast Cancer Immunotherapy Revenue in Global (US$, Mn）, 2018-2023
Table 13. By Type - Breast Cancer Immunotherapy Revenue in Global (US$, Mn）, 2024-2029
Table 14. By Application – Global Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2022 & 2029
Table 15. By Application - Breast Cancer Immunotherapy Revenue in Global (US$, Mn）, 2018-2023
Table 16. By Application - Breast Cancer Immunotherapy Revenue in Global (US$, Mn）, 2024-2029
Table 17. By Region – Global Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2022 & 2029
Table 18. By Region - Global Breast Cancer Immunotherapy Revenue (US$, Mn）, 2018-2023
Table 19. By Region - Global Breast Cancer Immunotherapy Revenue (US$, Mn）, 2024-2029
Table 20. By Country - North America Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2023
Table 21. By Country - North America Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2024-2029
Table 22. By Country - Europe Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2023
Table 23. By Country - Europe Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2024-2029
Table 24. By Region - Asia Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2023
Table 25. By Region - Asia Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2024-2029
Table 26. By Country - South America Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2023
Table 27. By Country - South America Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2024-2029
Table 28. By Country - Middle East & Africa Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2023
Table 29. By Country - Middle East & Africa Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2024-2029
Table 30. Roche Company Summary
Table 31. Roche Breast Cancer Immunotherapy Product Offerings
Table 32. Roche Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 33. Roche Key News & Latest Developments
Table 34. Genentech Company Summary
Table 35. Genentech Breast Cancer Immunotherapy Product Offerings
Table 36. Genentech Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 37. Genentech Key News & Latest Developments
Table 38. Amgen Company Summary
Table 39. Amgen Breast Cancer Immunotherapy Product Offerings
Table 40. Amgen Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 41. Amgen Key News & Latest Developments
Table 42. Antibody Therapeutics Company Summary
Table 43. Antibody Therapeutics Breast Cancer Immunotherapy Product Offerings
Table 44. Antibody Therapeutics Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 45. Antibody Therapeutics Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer Breast Cancer Immunotherapy Product Offerings
Table 48. Pfizer Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 49. Pfizer Key News & Latest Developments
Table 50. Merck Company Summary
Table 51. Merck Breast Cancer Immunotherapy Product Offerings
Table 52. Merck Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 53. Merck Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Breast Cancer Immunotherapy Product Offerings
Table 56. Novartis Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 57. Novartis Key News & Latest Developments
Table 58. Bristol Myers Squibb Company Summary
Table 59. Bristol Myers Squibb Breast Cancer Immunotherapy Product Offerings
Table 60. Bristol Myers Squibb Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 61. Bristol Myers Squibb Key News & Latest Developments
Table 62. Squibb Company Summary
Table 63. Squibb Breast Cancer Immunotherapy Product Offerings
Table 64. Squibb Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 65. Squibb Key News & Latest Developments
Table 66. EirGenix Company Summary
Table 67. EirGenix Breast Cancer Immunotherapy Product Offerings
Table 68. EirGenix Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 69. EirGenix Key News & Latest Developments
Table 70. Prestige BioPharma Company Summary
Table 71. Prestige BioPharma Breast Cancer Immunotherapy Product Offerings
Table 72. Prestige BioPharma Breast Cancer Immunotherapy Revenue (US$, Mn） & (2018-2023）
Table 73. Prestige BioPharma Key News & Latest Developments
List of Figures
Figure 1. Breast Cancer Immunotherapy Segment by Type in 2022
Figure 2. Breast Cancer Immunotherapy Segment by Application in 2022
Figure 3. Global Breast Cancer Immunotherapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Breast Cancer Immunotherapy Market Size: 2022 VS 2029 (US$, Mn）
Figure 6. Global Breast Cancer Immunotherapy Revenue, 2018-2029 (US$, Mn）
Figure 7. The Top 3 and 5 Players Market Share by Breast Cancer Immunotherapy Revenue in 2022
Figure 8. By Type - Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 9. By Application - Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 10. By Type - Global Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2022 & 2029
Figure 11. By Type - Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 12. By Application - Global Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2022 & 2029
Figure 13. By Application - Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 14. By Region - Global Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 15. By Country - North America Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 16. US Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 17. Canada Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 18. Mexico Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 19. By Country - Europe Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 20. Germany Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 21. France Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 22. U.K. Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 23. Italy Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 24. Russia Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 25. Nordic Countries Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 26. Benelux Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 27. By Region - Asia Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 28. China Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 29. Japan Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 30. South Korea Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 31. Southeast Asia Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 32. India Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 33. By Country - South America Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 34. Brazil Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 35. Argentina Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 36. By Country - Middle East & Africa Breast Cancer Immunotherapy Revenue Market Share, 2018-2029
Figure 37. Turkey Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 38. Israel Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 39. Saudi Arabia Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 40. UAE Breast Cancer Immunotherapy Revenue, (US$, Mn）, 2018-2029
Figure 41. Roche Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 42. Genentech Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 43. Amgen Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 44. Antibody Therapeutics Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 45. Pfizer Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 46. Merck Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 47. Novartis Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 48. Bristol Myers Squibb Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 49. Squibb Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 50. EirGenix Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）
Figure 51. Prestige BioPharma Breast Cancer Immunotherapy Revenue Year Over Year Growth (US$, Mn） & (2018-2023）

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 乳がん免疫療法のグローバル市場展望 2023年-2029年：モノクローナル抗体、免疫チェックポイント阻害剤、がんワクチン、その他(Breast Cancer Immunotherapy Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

乳がん免疫療法のグローバル市場展望 2023年-2029年：モノクローナル抗体、免疫チェックポイント阻害剤、がんワクチン、その他

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp